Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma
- Supplementary File 1:
ZIP-Document (ZIP, 5650 KiB)
Noonan, J.J.; Jarzabek, M.; Lincoln, F.A.; Cavanagh, B.L.; Pariag, A.R.; Juric, V.; Young, L.S.; Ligon, K.L.; Jahns, H.; Zheleva, D.; Prehn, J.H.M.; Rehm, M.; Byrne, A.T.; Murphy, B.M. Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. Cancers 2019, 11, 2005. https://doi.org/10.3390/cancers11122005
Noonan JJ, Jarzabek M, Lincoln FA, Cavanagh BL, Pariag AR, Juric V, Young LS, Ligon KL, Jahns H, Zheleva D, Prehn JHM, Rehm M, Byrne AT, Murphy BM. Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. Cancers. 2019; 11(12):2005. https://doi.org/10.3390/cancers11122005
Chicago/Turabian StyleNoonan, Janis J., Monika Jarzabek, Frank A. Lincoln, Brenton L. Cavanagh, Arhona R. Pariag, Viktorija Juric, Leonie S. Young, Keith L. Ligon, Hanne Jahns, Daniella Zheleva, Jochen H.M. Prehn, Markus Rehm, Annette T. Byrne, and Brona M. Murphy. 2019. "Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma" Cancers 11, no. 12: 2005. https://doi.org/10.3390/cancers11122005